Format

Send to

Choose Destination
Nat Rev Drug Discov. 2015 Jun;14(6):424-42. doi: 10.1038/nrd4573. Epub 2015 May 22.

Malaria medicines: a glass half full?

Author information

1
Medicines for Malaria Venture, 20 Route de Pré-Bois, 1215 Geneva 15, Switzerland.
2
1] Medicines for Malaria Venture, 20 Route de Pré-Bois, 1215 Geneva 15, Switzerland. [2] Division of Allergy and Infectious Diseases, Department of Medicine and Departments of Global Health and Microbiology, University of Washington, 750 Republican Street, Seattle, Washington 98195, USA.

Abstract

Despite substantial scientific progress over the past two decades, malaria remains a worldwide burden that causes hundreds of thousands of deaths every year. New, affordable and safe drugs are required to overcome increasing resistance against artemisinin-based treatments, treat vulnerable populations, interrupt the parasite life cycle by blocking transmission to the vectors, prevent infection and target malaria species that transiently remain dormant in the liver. In this Review, we discuss how the antimalarial drug discovery pipeline has changed over the past 10 years, grouped by the various target compound or product profiles, to assess progress and gaps, and to recommend priorities.

PMID:
26000721
DOI:
10.1038/nrd4573
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center